Soborg, Denmark

Tina Hummelshoj Glue

USPTO Granted Patents = 6 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Tina Hummelshoj Glue: Innovator in Complement Activation Inhibition

Introduction

Tina Hummelshoj Glue is a prominent inventor based in Soborg, Denmark. She has made significant contributions to the field of biomedical research, particularly in the development of innovative therapeutic solutions. With a total of 6 patents to her name, her work focuses on addressing critical health issues related to inflammation and autoimmune diseases.

Latest Patents

One of her latest patents is centered around chimeric inhibitor molecules of complement activation. This invention relates to novel chimeric molecules of ficolin-associated polypeptides, including fusion polypeptides designed for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, and thrombotic or coagulopathic diseases. Additionally, the patent encompasses nucleic acid molecules encoding these fusion polypeptides, as well as the vectors and host cells utilized in their production.

Career Highlights

Throughout her career, Tina has worked with notable organizations such as Omeros Corporation and Rigshospitalet. Her experience in these institutions has allowed her to advance her research and contribute to the development of groundbreaking medical therapies.

Collaborations

Tina has collaborated with esteemed colleagues, including Peter Garred and Mikkel-Ole Skjodt. These partnerships have further enriched her research endeavors and expanded the impact of her innovations.

Conclusion

Tina Hummelshoj Glue is a trailblazer in the field of complement activation inhibition, with a focus on developing therapeutic solutions for complex health conditions. Her innovative patents and collaborations highlight her commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…